This is a snippet of the transcript, sign up to read more.
Smithfield's situation is a bit more nuanced. Essentially, we had a pig that our management wanted—a very fast-growing and robust pig. The idea was to produce as much as possible to fill our packing plants. However, new management came in and decided to change the model. They wanted more pigs rather than heavier pigs, which completely altered our index. We had a four-dollar weighting for feed per pound, and that dropped significantly. This change would have taken us five to 10 years to adapt to competitively. So, management decided to purchase outside genetics to move in that direction more quickly. They purchased DNA Swine Genetics, PIC, and Topigs. The main reasons Smithfield chose to do more outsourcing were because no single supplier could meet our demand in the required time span. PIC took the East Coast, while DNA and Topigs covered the West Coast. Additionally, using multiple genetics suppliers allowed us to ensure we were getting the best deal.
This is a snippet of the transcript, sign up to read more.
That was the original thinking until you're forced to take a business to court because they haven't paid you, can't pay you, and have gone bankrupt. During the big PRRS and PED outbreaks, when people were going bankrupt and PIC was knocking on the door, PIC understood how bad that looked to the rest of the industry. That's when most were kind of forced into trying a royalty-type model.
This is a snippet of the transcript, sign up to read more.
This document may not be reproduced, distributed, or transmitted in any form or by any means including resale of any part, unauthorised distribution to a third party or other electronic methods, without the prior written permission of IP 1 Ltd.
IP 1 Ltd, trading as In Practise (herein referred to as "IP") is a company registered in England and Wales and is not a registered investment advisor or broker-dealer, and is not licensed nor qualified to provide investment advice.
In Practise reserves all copyright, intellectual and other property rights in the Content. The information published in this transcript (“Content”) is for information purposes only and should not be used as the sole basis for making any investment decision. Information provided by IP is to be used as an educational tool and nothing in this Content shall be construed as an offer, recommendation or solicitation regarding any financial product, service or management of investments or securities. The views of the executive expressed in the Content are those of the expert and they are not endorsed by, nor do they represent the opinion of In Practise. In Practise makes no representations and accepts no liability for the Content or for any errors, omissions, or inaccuracies will in no way be held liable for any potential or actual violations of laws, including without limitation any securities laws, based on Information sent to you by In Practise.
© 2025 IP 1 Ltd. All rights reserved.
Subscribe to access hundreds of interviews and primary research